Header Logo

Connection

Doris Benbrook to Female

Back to Details
This is a "connection" page, showing publications Doris Benbrook has written about Female.
Doris Benbrook
Connection Strength
1.420
Female
  1. Targeting HSP70-E7 Interaction With SHetA2: A Novel Therapeutic Strategy for Cervical Cancer. J Med Virol. 2024 Nov; 96(11):e70088.
    View in: PubMed
    Score: 0.076
  2. Platelet and epithelial cell interations can be modeled in cell culture, and are not affected by dihomo-gamma-linolenic acid. PLoS One. 2024; 19(8):e0309125.
    View in: PubMed
    Score: 0.075
  3. Association of Sialyl Tn antigen with cervical cancer lymph node status: An NRG oncology/GOG study. Gynecol Oncol. 2023 04; 171:67-75.
    View in: PubMed
    Score: 0.068
  4. Identification of Candidate Biomarker and Drug Targets for Improving Endometrial Cancer Racial Disparities. Int J Mol Sci. 2022 Jul 14; 23(14).
    View in: PubMed
    Score: 0.065
  5. Sera Protein Signatures of Endometrial Cancer Lymph Node Metastases. Int J Mol Sci. 2022 Mar 18; 23(6).
    View in: PubMed
    Score: 0.064
  6. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. Int J Cancer. 2020 08 15; 147(4):1086-1097.
    View in: PubMed
    Score: 0.055
  7. Tetrahydroquinoline units in flexible heteroarotinoids (Flex-Hets) convey anti-cancer properties in A2780 ovarian cancer cells. Bioorg Med Chem. 2020 01 01; 28(1):115244.
    View in: PubMed
    Score: 0.054
  8. Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors. Geroscience. 2018 06; 40(3):325-336.
    View in: PubMed
    Score: 0.049
  9. Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity. Tissue Cell. 2018 Jun; 52:57-64.
    View in: PubMed
    Score: 0.048
  10. Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. Invest New Drugs. 2018 08; 36(4):561-570.
    View in: PubMed
    Score: 0.047
  11. The pro-inflammatory effect of obesity on high grade serous ovarian cancer. Gynecol Oncol. 2016 10; 143(1):40-45.
    View in: PubMed
    Score: 0.043
  12. Insulin exerts direct effects on carcinogenic transformation of human endometrial organotypic cultures. Cancer Invest. 2014 Mar; 32(3):63-70.
    View in: PubMed
    Score: 0.036
  13. Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity. Cancer Prev Res (Phila). 2013 Sep; 6(9):908-16.
    View in: PubMed
    Score: 0.035
  14. A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Nov; 127(2):356-61.
    View in: PubMed
    Score: 0.033
  15. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. Gynecol Oncol. 2010 Dec; 119(3):444-50.
    View in: PubMed
    Score: 0.029
  16. NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis. Anticancer Drugs. 2010 Mar; 21(3):297-305.
    View in: PubMed
    Score: 0.028
  17. Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents. Gynecol Oncol. 2009 Dec; 115(3):438-42.
    View in: PubMed
    Score: 0.027
  18. Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. Cancer Res. 2009 Aug 15; 69(16):6565-72.
    View in: PubMed
    Score: 0.027
  19. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol. 2007 Sep; 106(3):596-603.
    View in: PubMed
    Score: 0.023
  20. Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. Mol Cancer Ther. 2007 Jun; 6(6):1814-22.
    View in: PubMed
    Score: 0.023
  21. Promise and problems of translational research. Gynecol Oncol. 2006 Nov; 103(2 Suppl 1):S14-7.
    View in: PubMed
    Score: 0.022
  22. Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. Invest New Drugs. 2005 Oct; 23(5):417-28.
    View in: PubMed
    Score: 0.020
  23. Sensitization of cervical cancer cell lines to low-dose radiation by retinoic acid does not require functional p53. Gynecol Oncol. 2005 Apr; 97(1):142-50.
    View in: PubMed
    Score: 0.020
  24. Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. J Med Chem. 2004 Feb 12; 47(4):999-1007.
    View in: PubMed
    Score: 0.018
  25. Pharmacodynamics of Cyclin D1 Degradation in Ovarian Cancer Xenografts with Repeated Oral SHetA2 Dosing. AAPS J. 2023 Dec 12; 26(1):5.
    View in: PubMed
    Score: 0.018
  26. Niclosamide causes lysosome-dependent cell death in endometrial cancer cells and tumors. Biomed Pharmacother. 2023 May; 161:114422.
    View in: PubMed
    Score: 0.017
  27. Association between Serum Biomarkers with Postoperative Complications and Delay of Adjuvant Chemotherapy Initiation in Ovarian Cancer Patients Undergoing Primary Cytoreductive Surgery: A Pilot Study. Nutr Cancer. 2023; 75(2):662-669.
    View in: PubMed
    Score: 0.017
  28. Retinoids and steroids regulate menstrual phase histological features in human endometrial organotypic cultures. Fertil Steril. 2002 Sep; 78(3):596-602.
    View in: PubMed
    Score: 0.016
  29. Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro. Gynecol Oncol. 2002 Apr; 85(1):223-5.
    View in: PubMed
    Score: 0.016
  30. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. J Natl Cancer Inst. 2001 Apr 04; 93(7):516-25.
    View in: PubMed
    Score: 0.015
  31. Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecol Oncol. 2021 01; 160(1):302-311.
    View in: PubMed
    Score: 0.014
  32. Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile. J Pharm Sci. 2020 06; 109(6):2000-2008.
    View in: PubMed
    Score: 0.014
  33. Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. AAPS J. 2020 02 21; 22(2):51.
    View in: PubMed
    Score: 0.014
  34. The mechanism of retinoic acid radiosensitization is independent of AP-1 repression in a cervical carcinoma cell line. Gynecol Oncol. 1999 May; 73(2):253-6.
    View in: PubMed
    Score: 0.013
  35. Chemically induced carcinogenesis in rodent models of aging: assessing organismal resilience to genotoxic stressors in geroscience research. Geroscience. 2019 04; 41(2):209-227.
    View in: PubMed
    Score: 0.013
  36. Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780. Eur J Med Chem. 2019 May 15; 170:16-27.
    View in: PubMed
    Score: 0.013
  37. Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2. Eur J Med Chem. 2018 Oct 05; 158:720-732.
    View in: PubMed
    Score: 0.012
  38. Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice. J Pharm Sci. 2018 12; 107(12):3179-3186.
    View in: PubMed
    Score: 0.012
  39. Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration. Eur J Pharm Biopharm. 2018 Sep; 130:272-280.
    View in: PubMed
    Score: 0.012
  40. Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. Cancer Lett. 2018 07 01; 425:174-182.
    View in: PubMed
    Score: 0.012
  41. Optimization of a Vaginal Suppository Formulation to Deliver SHetA2 as a Novel Treatment for Cervical Dysplasia. J Pharm Sci. 2018 02; 107(2):638-646.
    View in: PubMed
    Score: 0.012
  42. Biological assay for activity and molecular mechanism of retinoids in cervical tumor cells. Gynecol Oncol. 1997 Jul; 66(1):114-21.
    View in: PubMed
    Score: 0.011
  43. Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. Gynecol Oncol. 1997 Jun; 65(3):425-9.
    View in: PubMed
    Score: 0.011
  44. Differential retinoic acid radiosensitization of cervical carcinoma cell lines. Clin Cancer Res. 1997 Jun; 3(6):939-45.
    View in: PubMed
    Score: 0.011
  45. A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 05; 145(2):291-297.
    View in: PubMed
    Score: 0.011
  46. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. Oncol Rep. 2017 Apr; 37(4):2382-2390.
    View in: PubMed
    Score: 0.011
  47. Aberrant NRP-1 expression serves as predicator of metastatic endometrial and lung cancers. Oncotarget. 2016 Feb 16; 7(7):7970-8.
    View in: PubMed
    Score: 0.010
  48. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol. 2016 Jan; 27(1):e8.
    View in: PubMed
    Score: 0.010
  49. Immunohistochemical analysis of proliferation and differentiation in organotypic cultures of cervical tumor cell lines. Tissue Cell. 1995 Jun; 27(3):269-74.
    View in: PubMed
    Score: 0.010
  50. Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line. Eur J Med Chem. 2015; 96:209-17.
    View in: PubMed
    Score: 0.010
  51. A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):38-43.
    View in: PubMed
    Score: 0.009
  52. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol Oncol. 2014 Apr; 133(1):11-5.
    View in: PubMed
    Score: 0.009
  53. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):377-82.
    View in: PubMed
    Score: 0.009
  54. Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs. Drug Chem Toxicol. 2013 Jul; 36(3):284-95.
    View in: PubMed
    Score: 0.008
  55. Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen. Mutat Res. 2012 Jul 04; 746(1):78-88.
    View in: PubMed
    Score: 0.008
  56. Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo. Oncogene. 2012 May 31; 31(22):2725-37.
    View in: PubMed
    Score: 0.008
  57. Clioquinol suppresses cyclin D1 gene expression through transcriptional and post-transcriptional mechanisms. Anticancer Res. 2011 Sep; 31(9):2739-47.
    View in: PubMed
    Score: 0.008
  58. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011 Jun 01; 121(3):455-61.
    View in: PubMed
    Score: 0.007
  59. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res. 2008 Jul 01; 68(13):5335-44.
    View in: PubMed
    Score: 0.006
  60. Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. Cancer Res. 2008 Mar 15; 68(6):1636-46.
    View in: PubMed
    Score: 0.006
  61. A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. Gynecol Oncol. 2007 May; 105(2):508-16.
    View in: PubMed
    Score: 0.006
  62. Nonphotochemical hole-burning study of selectively stained normal and cancerous human ovarian tissues. J Phys Chem B. 2006 Aug 17; 110(32):16124-30.
    View in: PubMed
    Score: 0.005
  63. Retinoid activation of retinoic acid receptor but not retinoid X receptor is sufficient to rescue lethal defect in retinoic acid synthesis. Proc Natl Acad Sci U S A. 2003 Jun 10; 100(12):7135-40.
    View in: PubMed
    Score: 0.004
  64. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. Clin Cancer Res. 2002 Nov; 8(11):3520-6.
    View in: PubMed
    Score: 0.004
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.